• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Warby Parker Inc.

    2/27/25 5:00:06 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    S-8 1 tm257754d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Warby Parker Inc.

    (Exact name of Registrant as specified in its charter)

     

         
    Delaware   80-0423634

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    233 Spring Street, 6th Floor East

    New York, New York 10013

    (646) 847-7215

    (Address of principal executive offices) (Zip code)

     

    Warby Parker Inc. 2021 Incentive Award Plan

    Warby Parker Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

     

     

    Neil Blumenthal, Co-Founder and Co-Chief Executive Officer

    Dave Gilboa, Co-Founder and Co-Chief Executive Officer

    Warby Parker Inc.

    233 Spring Street, 6th Floor East

    New York, New York 10013

    (646) 847-7215

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    With copies to:

    Steven Miller
    Chris Utecht
    Lindsay Buxbaum
    Warby Parker Inc.
    233 Spring Street, 6th Floor East
    New York, New York 10013
    (646) 847-7215
     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer x   Accelerated filer ¨  
             
      Non-accelerated filer ¨     Smaller reporting company ¨  
             
          Emerging growth company ¨  

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 6,035,574 shares of Warby Parker Inc.’s (the “Registrant”) Class A common stock, $0.0001 par value per share (“Class A common stock”), to be issued pursuant to the Warby Parker Inc. 2021 Incentive Award Plan (the “2021 Plan”) and an additional 1,207,114 shares of the Registrant’s Class A common stock to be issued pursuant to the Warby Parker Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”) and for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

     

    The contents of the Registration Statements on Form S-8 (File Nos. 333-259703, 333-263698,333-270140 and 333-277548), filed with the Securities and Exchange Commission, relating to the 2021 Plan and the 2021 ESPP, are incorporated herein by reference.

     

    Item 8. Exhibits

     

    Exhibit Number   Description
         
    4.1   Specimen Class A common stock certificate of Warby Parker Inc. (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-259035) filed on August 24, 2021)
         
    4.2   Specimen Class B common stock certificate of Warby Parker Inc. (incorporated by reference to Exhibit 4.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40825) filed on May 16, 2022)
         
    4.3   Twelfth Amended and Restated Certificate of Incorporation of Warby Parker Inc. (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-259704) filed on September 22, 2021)
         
    4.4   Amended and Restated Bylaws of Warby Parker Inc. (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-259704) filed on September 22, 2021)
         
    5.1*   Opinion of Latham & Watkins LLP
         
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
         
    23.2*   Consent of Latham & Watkins LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included on signature page)
         
    99.1   Warby Parker Inc. 2021 Incentive Award Plan and related form agreements (incorporated by reference to Exhibit 10.5 to the Registrant's Annual Report on Form 10-K (File No. 001-40825) filed on February 29, 2024)
         
    99.2   Warby Parker Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-40825) filed on February 29, 2024)
         
    107.1*   Filing Fee Table

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on February 27, 2025.

      WARBY PARKER INC.
       
      By: /s/ Neil Blumenthal
        Neil Blumenthal
        Co-Chief Executive Officer
       
      By: /s/ Dave Gilboa
        Dave Gilboa
        Co-Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Neil Blumenthal, Dave Gilboa, and Steven Miller, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Neil Blumenthal   Co-Chief Executive Officer and Director
    (Co-Principal Executive Officer)
      February 27, 2025
    Neil Blumenthal        
             
    /s/ Dave Gilboa   Co-Chief Executive Officer and Director
    (Co-Principal Executive Officer)
      February 27, 2025
    Dave Gilboa        
             
    /s/ Steven Miller   Chief Financial Officer   February 27, 2025
    Steven Miller   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Andrew Hunt   Director   February 27, 2025
    Andrew Hunt        
             
    /s/ Jeffrey Raider   Director   February 27, 2025
    Jeffrey Raider        
             
    /s/ Teresa Briggs   Director   February 27, 2025
    Teresa Briggs        
             
    /s/ Joel Cutler   Director   February 27, 2025
    Joel Cutler        
             
    /s/ Youngme Moon   Director   February 27, 2025
    Youngme Moon        
             
    /s/ Bradley Singer   Director   February 27, 2025
    Bradley Singer        
             
    /s/ Ronald A. Williams   Director   February 27, 2025
    Ronald A. Williams        

     

     

     

    Get the next $WRBY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    2/5/2025$19.00 → $23.00Neutral → Sell
    Citigroup
    1/17/2025$23.00Outperform → In-line
    Evercore ISI
    11/19/2024$22.00 → $26.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Warby Parker to Announce Second Quarter 2025 Financial Results August 7, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the second quarter ended June 30, 2025 will be released before market open on August 7, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 754099. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where present

      7/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Announces Participation in the Baird Global Consumer, Technology & Services Conference

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Baird Global Consumer, Technology & Services Conference Tuesday, June 3, 2025 at 10:50 a.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com/. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co

      6/2/25 7:00:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Partners with Google To Develop Intelligent Eyewear

      AI-Powered Glasses Will Be Designed for All-Day Wear Announcement Marks First Eyewear Partnership for Android XR Google Commits Up to $150M, Including an Equity Investment in Warby Parker, as Part of Long-Term Commitment to Partnership Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to develop AI-powered glasses intended for all-day wear. The partnership will combine Warby Parker's signature approach to eyewear design with Google's industry-leading technology ecosystem, bringing the next generation of computing to a new form factor: glasses. "Since our launch we've set out to transfo

      5/20/25 1:58:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Co-Chief Executive Officer Gilboa David Abraham converted options into 50,000 shares and sold $1,102,000 worth of shares (50,000 units at $22.04) (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      7/3/25 5:00:38 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Director Moon Youngme E was granted 12,020 shares, increasing direct ownership by 22% to 65,889 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      6/12/25 7:05:24 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Director Briggs Teresa was granted 12,020 shares, increasing direct ownership by 31% to 50,879 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      6/12/25 7:03:46 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Warby Parker downgraded by Citizens JMP

      Citizens JMP downgraded Warby Parker from Mkt Outperform to Mkt Perform

      7/10/25 8:37:20 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker upgraded by Citigroup with a new price target

      Citigroup upgraded Warby Parker from Sell to Neutral and set a new price target of $17.00

      4/30/25 1:18:55 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker upgraded by Loop Capital with a new price target

      Loop Capital upgraded Warby Parker from Hold to Buy and set a new price target of $27.00

      4/17/25 8:27:42 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      8/14/24 4:52:02 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    SEC Filings

    See more
    • SEC Form 144 filed by Warby Parker Inc.

      144 - Warby Parker Inc. (0001504776) (Subject)

      7/1/25 4:32:50 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • SEC Form 144 filed by Warby Parker Inc.

      144 - Warby Parker Inc. (0001504776) (Subject)

      5/22/25 4:29:29 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Warby Parker Inc. (0001504776) (Filer)

      5/20/25 2:24:32 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

      Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

      8/1/24 4:15:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Financials

    Live finance-specific insights

    See more

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Warby Parker to Announce Second Quarter 2025 Financial Results August 7, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the second quarter ended June 30, 2025 will be released before market open on August 7, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 754099. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where present

      7/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 5:08:23 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 1:30:16 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/12/24 10:40:28 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care